Classification and comparison of ligand-binding sites derived from grid-mapped knowledge-based potentials.

We describe the application of knowledge-based potentials implemented in the MOE program to compare the ligand-binding sites of several proteins. The binding probabilities for a polar and a hydrophobic probe are calculated on a grid to allow easy comparison of binding sites of superimposed related proteins. The method is fast and simple enough to simultaneously use structural information of multiple proteins of a target family. The method can be used to rapidly cluster proteins into subfamilies according to the similarity of hydrophobic and polar fields of their ligand-binding sites. Regions of the binding site which are common within a protein family can be identified and analysed for the design of family-targeted libraries or those which differ for improvement of ligand selectivity. The field-based hierarchical clustering is demonstrated for three protein families: the ligand-binding domains of nuclear receptors, the ATP-binding sites of protein kinases and the substrate binding sites of proteases. More detailed comparisons are presented for serine proteases of the chymotrypsin family, for the peroxisome proliferator-activated receptor subfamily of nuclear receptors and for progesterone and androgen receptor. The results are in good accordance with structure-based analysis and highlight important differences of the binding sites, which have been also described in the literature.

[1]  M. Karplus,et al.  Effective energy functions for protein structure prediction. , 2000, Current opinion in structural biology.

[2]  David H. Williams,et al.  Latest developments in crystallography and structure-based design of protein kinase inhibitors as drug candidates. , 2002, Current opinion in pharmacology.

[3]  Robert P Sheridan,et al.  A simple method for visualizing the differences between related receptor sites. , 2002, Journal of molecular graphics & modelling.

[4]  D. Tobi,et al.  Sequence-based Design of Kinase Inhibitors Applicable for Therapeutics and Target Identification* , 2004, Journal of Biological Chemistry.

[5]  Eunsun Lee,et al.  Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. , 2002, Journal of medicinal chemistry.

[6]  Z. Deng,et al.  Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. , 2004, Journal of medicinal chemistry.

[7]  Giulia Caron,et al.  Contribution of ionization and lipophilicity to drug binding to albumin: a preliminary step toward biodistribution prediction. , 2004, Journal of medicinal chemistry.

[8]  A. Tulinsky,et al.  Highly selective mechanism-based thrombin inhibitors: structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes. , 1998, Biochemistry.

[9]  D. Schomburg,et al.  BRAGI: a comprehensive protein modeling program system , 1988 .

[10]  Alexander Levitzki,et al.  Protein kinase inhibitors as a therapeutic modality. , 2003, Accounts of chemical research.

[11]  Gerhard Klebe,et al.  Understanding protein-ligand interactions: the price of protein flexibility. , 2004, Journal of molecular biology.

[12]  S. Pickett,et al.  GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. , 2000, Journal of medicinal chemistry.

[13]  U. Lessel,et al.  Similarities between protein 3-D structures. , 1994, Protein engineering.

[14]  J M Thornton,et al.  X-SITE: use of empirically derived atomic packing preferences to identify favourable interaction regions in the binding sites of proteins. , 1996, Journal of molecular biology.

[15]  James M. Hogle,et al.  Functional group placement in protein binding sites: a comparison of GRID and MCSS , 2001, J. Comput. Aided Mol. Des..

[16]  Robin Taylor,et al.  SuperStar: a knowledge-based approach for identifying interaction sites in proteins. , 1999, Journal of molecular biology.

[17]  Qi Sun,et al.  Slit Branches Out A Secreted Protein Mediates Both Attractive and Repulsive Axon Guidance , 1999, Cell.

[18]  M. A. Carrondo,et al.  Structural Basis for the Glucocorticoid Response in a Mutant Human Androgen Receptor (ARccr) Derived from an Androgen-Independent Prostate Cancer , 2002 .

[19]  R C Wade,et al.  Identifying targets for bioreductive agents: using GRID to predict selective binding regions of proteins. , 1989, Journal of molecular graphics.

[20]  Giulia Caron,et al.  Docking studies on NSAID/COX-2 isozyme complexes using Contact Statistics analysis , 2004, J. Comput. Aided Mol. Des..

[21]  M. Karplus,et al.  Functionality maps of binding sites: A multiple copy simultaneous search method , 1991, Proteins.

[22]  Miss A.O. Penney (b) , 1974, The New Yale Book of Quotations.

[23]  D. Moras,et al.  Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor 3. , 2002, Molecular cell.

[24]  Mika A. Kastenholz,et al.  GRID/CPCA: a new computational tool to design selective ligands. , 2000, Journal of medicinal chemistry.

[25]  Knut Baumann,et al.  Structure-Based Validation of the 3D-QSAR Technique MaP , 2005, J. Chem. Inf. Model..

[26]  L. Johnson,et al.  Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.

[27]  Gert Vriend,et al.  Collecting and harvesting biological data: the GPCRDB and NucleaRDB information systems , 2001, Nucleic Acids Res..

[28]  Peter Willett,et al.  A bibliometric analysis of the Journal of Molecular Graphics and Modelling. , 2007, Journal of molecular graphics & modelling.

[29]  J. Edwards,et al.  5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators. , 2003, Journal of medicinal chemistry.

[30]  Robin Taylor,et al.  IsoStar: A library of information about nonbonded interactions , 1997, J. Comput. Aided Mol. Des..

[31]  M Carlquist,et al.  Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist , 1999, The EMBO journal.

[32]  Peter Scholz,et al.  Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor , 2000, The Journal of Biological Chemistry.

[33]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  T. Kaminuma Pathways and Networks of Nuclear Receptors and Modeling of Syndrome X , 2003 .

[35]  M. Berenbaum,et al.  Molecular docking of substrates and inhibitors in the catalytic site of CYP6B1, an insect cytochrome p450 monooxygenase. , 2003, Protein Engineering.

[36]  Robert P. Sheridan,et al.  Calculating Similarities between Biological Activities in the MDL Drug Data Report Database , 2004, J. Chem. Inf. Model..

[37]  Bernard Pirard,et al.  Peroxisome Proliferator-Activated Receptors target family landscape: A chemometrical approach to ligand selectivity based on protein binding site analysis , 2003, J. Comput. Aided Mol. Des..

[38]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[39]  Ettore Novellino,et al.  A Critical Review of Recent CoMFA Applications , 1998 .

[40]  Ricardo Coelho,et al.  Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. , 2002, Journal of medicinal chemistry.

[41]  Antti Poso,et al.  BRUTUS: optimization of a grid-based similarity function for rigid-body molecular superposition. 1. Alignment and virtual screening applications. , 2005, Journal of medicinal chemistry.

[42]  Jussi Parkkinen,et al.  BRUTUS: Optimization of a grid-based similarity function for rigid-body molecular superposition. II. Description and characterization , 2006, J. Comput. Aided Mol. Des..

[43]  G L Trainor,et al.  Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. , 2000, Journal of medicinal chemistry.

[44]  G. Klebe,et al.  DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein. , 2002, Journal of medicinal chemistry.

[45]  Brian K Shoichet,et al.  Kinase inhibitors: not just for kinases anymore. , 2003, Journal of medicinal chemistry.

[46]  H. Matter,et al.  Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes. , 2002, Journal of medicinal chemistry.

[47]  Richard Morphy,et al.  From magic bullets to designed multiple ligands. , 2004, Drug discovery today.

[48]  M Pastor,et al.  A novel strategy for improving ligand selectivity in receptor-based drug design. , 1995, Journal of medicinal chemistry.

[49]  M. A. Carrondo,et al.  Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. , 2000, The Journal of biological chemistry.

[50]  Peter Wolohan,et al.  CoMFA and docking study of novel estrogen receptor subtype selective ligands , 2003, J. Comput. Aided Mol. Des..

[51]  M. Verdonk,et al.  SuperStar: comparison of CSD and PDB-based interaction fields as a basis for the prediction of protein-ligand interactions. , 2001, Journal of molecular biology.